FindTrial
Sign In

68Ga-DOTATATE PET/CT

DRUG5 trials

Sponsors

Jewish General Hospital, Mayo Clinic, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), British Columbia Cancer Agency

Conditions

Atheroscleroses, CoronaryCardiac SarcoidosisMedullary Thyroid CarcinomaNeuroendocrine TumorsNeuroendocrine Tumors, NETOsteomalaciaPheochromocytoma/ParagangliomaSSTR-expressing Tumors

Phase 1

Ga-DOTATATE PET for Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced Osteomalacia
CompletedNCT03736564
Mayo ClinicOsteomalacia
Start: 2019-01-31End: 2023-10-31Updated: 2025-04-30

Phase 3

SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors
CompletedNCT02840149
Jewish General HospitalNeuroendocrine Tumors
Start: 2019-10-01End: 2023-12-13Updated: 2025-05-15

Phase 4

d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis
CompletedNCT03549598
Mayo ClinicCardiac Sarcoidosis
Start: 2018-07-20End: 2019-10-02Updated: 2020-10-20

Unknown Phase

Dotatate to Locate Coronary Plaques at High-risk of Myocardial Infarction
CompletedNCT05536960
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Atheroscleroses, Coronary
Start: 2022-09-09End: 2023-10-06Updated: 2024-02-14
A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies
Not yet recruitingNCT07621146
British Columbia Cancer AgencyMedullary Thyroid Carcinoma, Neuroendocrine Tumors, NET, Pheochromocytoma/Paraganglioma +1
Start: 2026-09-15End: 2028-03-01Target: 51Updated: 2026-06-02